Xeptiva Therapeutics

  • Home
  • Company
    • About us
    • Team
  • Innovation
    • Technology
    • Pipeline
    • Target diseases
  • Clinical Trials
    • Chronic Pain
    • Atopic Dermatitis
  • News
    • See news
    • Press
  • Blog
  • Contact
  • Home
  • Company
    • About us
    • Team
  • Innovation
    • Technology
    • Pipeline
    • Target diseases
  • Clinical Trials
    • Chronic Pain
    • Atopic Dermatitis
  • News
    • See news
    • Press
  • Blog
  • Contact


​NEWS

Valentina Varela leads new publication in Biotechnology Reports on rNGFSP, the technology behind Xep01
Valentina Varela leads new publication in Biotechnology Reports on rNGFSP, the technology behind Xep01
Xeptiva Therapeutics was recognized as a finalist in the Start-up category of the PwC Uruguay Innovation Award 2025
Athos Therapeutics and Xeptiva Therapeutics Announce Partnership to Discover Vaccine Biomarkers
Celebrating Excellence: Dr. Luis Barbeito Wins the National Science Grand Prize 2024
Xeptiva Therapeutics raised $2.5M seed round
The first industrial batch of our vaccine has been produced!
New government grant for Xeptiva Therapeutics
Institut Pasteur de Montevideo & Xeptiva Therapeutics
Pasaporte Emprendedor
WeXchange
New Government Grant for Xeptiva Therapeutics
Government Grant for Xeptiva Therapeutics and the Institut Pasteur de Montevideo
Xeptiva Therapeutics, a biotech startup born in the Institut Pasteur de Montevideo, advances in its development
World Neuroscience Organization awards Emiliano Trías, a Uruguayan scientist, with the IBRO Young Investigator Award 2021

COMPANY

About Us
Team

INNOVATION

Technology
Pipeline
Target diseases

clinical trial

NEWS

See News
Press releases

cONTACT

BLOG

© COPYRIGHT 2025.  ALL RIGHTS RESERVED.